Effect of a CCK-1R Agonist on Food Intake in Humans

Summary

The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK) agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The study will be conducted in phases. First, an effective dose for reducing food intake, when normal subjects eat normally will be attained. Next, it will be determined whether intake at this dose is reduced in control subjects instructed to eat to capacity. If the dose is still effective compared to placebo, the same dose will be tested in patients with bulimia nervosa.

Timeline

Start

2008-01

Primary completion

2009-02

Completion

2009-02

Outcome

Outcome not reported

Stopped: “Drug expired before was completed.”

Drugs

Indications